Compare ADT Inc (ADT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADT Inc vs Summit Therapeutics Inc — how do they compare? ADT Inc trades at $6.73 (market cap $5.07B), while Summit Therapeutics Inc trades at $15.62 (market cap $12.32B). The key difference: Summit Therapeutics Inc is far larger — about 2.4× ADT Inc's market cap, and ADT Inc pays a 3.18% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ADT | SMMT | |
|---|---|---|
Market Cap | $5.07B | $12.32B |
Sector | Industrials | Health |
52-Week High | $8.85 | $29.32 |
52-Week Low | $6.30 | $13.05 |
Enterprise Value | $12.62B | $11.74B |
Dividend Yield | 3.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADT trades at $6.91, up 1.17% today, with a bullish technical signal and consistent earnings beats. The company shows strong profitability with an 80.82% gross margin and 12.14% net margin, supported by positive news including recent industry awards and board participation in the Connectivity Standards Alliance. Cash flow from operations remains robust at $1.88 billion for 2025, though net cash flow was slightly negative.
Outlook is positive with analyst consensus leaning buy (47% buy ratings), but risks include high long-term debt of $7.51 billion and competitive pressures in home security. Revenue growth is stable, and valuation metrics like P/E of 8.88 suggest potential undervaluation, making it attractive for value-oriented investors mindful of leverage.
Summit Therapeutics (SMMT) trades at $15.93, up 3.31% today, with a bullish technical signal despite mixed moving averages and overbought RSI readings. The company reported a net loss of -$1.08B in 2025 and negative ROE/ROA, but recent Phase III trial success for ivonescimab in lung cancer has driven optimism. Cash flow remains volatile, with 2025 net cash flow positive at $120.4M but turning negative in 2026 projections.
Outlook hinges on ivonescimab's regulatory approval and commercial potential, with a consensus price target of $22.93 implying 44% upside. High volatility and binary clinical outcomes pose significant risks, but strong analyst buy ratings (66.7%) reflect confidence in the drug's prospects. Investors face substantial dilution risk from a proposed $500M stock offering announced June 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Read more on ADT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
